Desloratadine for chronic idiopathic urticaria

Harefuah

Volumn 144, Issue 8, 2005, Pages 547-553

  Rottem, Menachem ^a,b   Elbirt, Daniel ^e   Sthoeger, Zev ^c,d  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY   (Israel)

^e NONE

Author keywords

Antihistamines; Chronic idiopathic urticaria; Desolratadine

Indexed keywords

DESLORATADINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ARTICLE; CHRONIC URTICARIA; HUMAN; IDIOPATHIC DISEASE; ADULT; AGED; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; ISRAEL; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; ISRAEL; LORATADINE; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; URTICARIA;

EID: 25444497774     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Greaves MW, Chronic urticaria. New Engl J Med, 1995; 332: 1767-1772.
2. Sabroe RA & Greaves MW, The pathogenesis of chronic idiopathic urticaria. Arch Dermatol, 1997; 133: 1003-1008.
3. Kozel MM & Sabroe RA, Chronic urticaria: etiology, management and current and future treatment options. Drugs, 2004; 64: 2515-2536.
4. Rottem M, Chronic urticaria and autoimmune thyroid disease: is there a link? Autoimmun Rev, 2003; 2: 69-72.
5. Kaplan AP, Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol, 2004; 114: 465-474.
6. Ring J, Hein R, Gauger A & al, Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001; 40: 72-76.
7. Monroe E, Finn A, Patel P & al, Desloratadine Uritcaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol, 2003; 48: 535-541.
8. Agrawal DK, Anti-inflammatory properties of desloratadine. Clin Exp Allergy, 2004; 34: 1342-1348.
9. Wang YH, Tache Y, Harris AG & al, Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy, 2005; 60: 117-124.
10. Kreutner W, Hey JA, Anthes J & al, Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 2000; 50: 345-352.
11. Murdoch D, Goa KL & Keam SJ, Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs, 2003; 63: 2051-2077.